Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.
| Revenue (TTM) | $34.56M |
| Gross Profit (TTM) | $-78.11M |
| EBITDA | $-106.66M |
| Operating Margin | -2215.00% |
| Return on Equity | -2892.00% |
| Return on Assets | -94.40% |
| Revenue/Share (TTM) | $0.11 |
| Book Value | $-0.04 |
| Price-to-Book | 18.13 |
| Price-to-Sales (TTM) | 2.40 |
| EV/Revenue | 2.159 |
| EV/EBITDA | -1.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -77.60% |
| Shares Outstanding | $414.29M |
| Float | $410.04M |
| % Insiders | 1.77% |
| % Institutions | 25.85% |
Volatility is currently expanding
Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503 in chronic neuropathic pain.
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three Sangamo abstracts for presentation at the 29th ASGCT Annual Meeting being held May 11-15, 2026, in-person in Boston, MA and in a virtual format.
RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026.
